BR112018012826A2 - método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1 - Google Patents

método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1

Info

Publication number
BR112018012826A2
BR112018012826A2 BR112018012826A BR112018012826A BR112018012826A2 BR 112018012826 A2 BR112018012826 A2 BR 112018012826A2 BR 112018012826 A BR112018012826 A BR 112018012826A BR 112018012826 A BR112018012826 A BR 112018012826A BR 112018012826 A2 BR112018012826 A2 BR 112018012826A2
Authority
BR
Brazil
Prior art keywords
specific
tcr
antigen
lymphocytes
mhc class
Prior art date
Application number
BR112018012826A
Other languages
English (en)
Inventor
Milosevic Slavoljub
Ellinger Christian
Wehner Carina
Schendel Dolores
Original Assignee
Medigene Immunotherapies Gmbh
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Immunotherapies Gmbh, Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) filed Critical Medigene Immunotherapies Gmbh
Publication of BR112018012826A2 publication Critical patent/BR112018012826A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção contempla métodos para a geração de linfócitos t antígeno-específicos humanos. os métodos empregam sinais de direcionamento de mhc classe ii fusionados a um antígeno ou fragmento do mesmo para obter apresentação de classe mhc de proteínas codificadas pelo rna. consequentemente, a presente invenção refere-se a vetores de expressão que compreendem sinal de direcionamento de mhc classe ii e pelo menos um antígeno ou fragmento do mesmo e seu uso para a geração in vitro de linfócitos t antígeno-específicos. clones de células t e receptores de células t (tcrs) específicos para antígenos tumorais ou antígenos virais também são descritos.
BR112018012826A 2015-12-23 2016-12-22 método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1 BR112018012826A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15202329 2015-12-23
EP16190399 2016-09-23
PCT/EP2016/082443 WO2017109109A1 (en) 2015-12-23 2016-12-22 Novel generation of antigen-specific tcrs

Publications (1)

Publication Number Publication Date
BR112018012826A2 true BR112018012826A2 (pt) 2018-12-04

Family

ID=57794260

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018012694A BR112018012694A2 (pt) 2015-12-23 2016-12-22 composição de célula dendrítica, vacina de célula dendrítica, composição e kit
BR112018012826A BR112018012826A2 (pt) 2015-12-23 2016-12-22 método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112018012694A BR112018012694A2 (pt) 2015-12-23 2016-12-22 composição de célula dendrítica, vacina de célula dendrítica, composição e kit

Country Status (17)

Country Link
US (2) US10882891B2 (pt)
EP (4) EP3394247B1 (pt)
JP (3) JP6697562B2 (pt)
KR (4) KR20200100858A (pt)
CN (2) CN108473960A (pt)
AU (2) AU2016374873B2 (pt)
BR (2) BR112018012694A2 (pt)
CA (2) CA3009542C (pt)
DK (2) DK3394248T3 (pt)
EA (2) EA201891460A1 (pt)
ES (2) ES2865484T3 (pt)
HU (1) HUE053674T2 (pt)
MX (2) MX2018007841A (pt)
PH (2) PH12018501336A1 (pt)
PL (2) PL3394247T3 (pt)
TW (2) TWI752930B (pt)
WO (2) WO2017109109A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922950B (zh) 2015-06-01 2021-12-31 基因医疗免疫疗法有限责任公司 T细胞受体文库
EA201792661A1 (ru) 2015-06-01 2018-05-31 Медиджин Иммьюнотерапиз Гмбх Способ получения антител против т-клеточного рецептора
JP6697562B2 (ja) 2015-12-23 2020-05-20 メディジーン イミュノテラピーズ ゲーエムベーハー 樹状細胞組成物
EA202091335A1 (ru) * 2017-12-04 2020-10-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
US10808465B2 (en) * 2018-04-27 2020-10-20 Canrig Robotic Technologies As System and method for conducting subterranean operations
US11015402B2 (en) 2018-04-27 2021-05-25 Canrig Robotic Technologies As System and method for conducting subterranean operations
US20210139852A1 (en) 2018-06-21 2021-05-13 Universiteit Gent Method for the in vitro differentiation and maturation of dendritic cells for therapeutic use
CN110172091B (zh) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
EP3977121A1 (en) * 2019-06-03 2022-04-06 The Scripps Research Institute A chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy
JP2023509527A (ja) * 2020-01-10 2023-03-08 エルジー・ケム・リミテッド Ｍｈｃおよび腫瘍抗原を同時発現する抗原提示細胞を含む組成物およびこれを用いた癌治療
CN112133372B (zh) * 2020-08-18 2022-06-03 北京臻知医学科技有限责任公司 抗原特异性tcr数据库的建立方法及抗原特异性tcr的评估方法
KR20220052299A (ko) * 2020-10-20 2022-04-27 연세대학교 산학협력단 단일 세포 분석법을 이용한 tcr-항원의 특이성을 확인하는 방법
WO2022115415A1 (en) * 2020-11-24 2022-06-02 Providence Health & Services - Oregon T cell receptors specific for a mutant form of the ret oncogene and uses thereof
WO2023060163A2 (en) * 2021-10-06 2023-04-13 Board Of Regents, The University Of Texas System Shp1 modified dendritic cells and extracellular vesicles derived therefrom and associated methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
KR920703844A (ko) 1989-11-15 1992-12-18 원본 미기재 사람에 있어 t-세포 표면 항원의 측정방법
AU652959B2 (en) 1990-08-09 1994-09-15 National Jewish Center For Immunology And Respiratory Medicine Producing monoclonal antibodies against human T-cell receptor elements using recombinant DNA vectors
DE69126301T2 (de) 1990-11-27 1998-01-02 Biogen Inc Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
US5480895A (en) 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
JP2702285B2 (ja) 1992-08-21 1998-01-21 バイオジェン，インコーポレイテッド Ｔａｔ由来の輸送ポリペプチド
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19625191A1 (de) 1996-06-24 1998-01-02 Boehringer Mannheim Gmbh Nierenkarzinom-spezifische T-Zellen
US6284879B1 (en) * 1998-04-16 2001-09-04 The General Hospital Corporation Transport associated protein splice variants
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
EP1259601A2 (en) 2000-02-22 2002-11-27 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
ES2347762T3 (es) * 2000-04-28 2010-11-04 Mannkind Corporation Sincronizacion de epitopos en celulas que presentan antigenos.
IL136459A0 (en) 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
FR2822846B1 (fr) 2001-04-03 2004-01-23 Technopharm Procede de preparation et de selection d'anticorps
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
NZ539226A (en) 2002-11-09 2008-09-26 Medigene Ltd T cell receptor display
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
PT2327763T (pt) 2005-08-05 2018-05-11 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Geração de células t específicas de antigénios
JP2007097580A (ja) 2005-09-06 2007-04-19 Shizuoka Prefecture Ｔ細胞レセプターβ鎖遺伝子
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
PT2016102E (pt) 2006-05-03 2012-05-15 Us Gov Health & Human Serv Recetores de célula t quimérica e materiais relacionados e métodos de uso
JP2010538018A (ja) * 2007-08-30 2010-12-09 ジェネンテック， インコーポレイテッド Ｔ細胞を調節するための方法及び組成物
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
US8394778B1 (en) * 2009-10-08 2013-03-12 Immune Disease Institute, Inc. Regulators of NFAT and/or store-operated calcium entry
WO2011053789A2 (en) * 2009-10-30 2011-05-05 James Cameron Oliver Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
EP2542683B1 (en) 2010-03-02 2017-01-25 F. Hoffmann-La Roche AG Expression vector
CN102719399A (zh) * 2012-04-28 2012-10-10 北京爱根生物科技有限公司 自体特异性t细胞的体外扩增方法及所制备的t细胞体系、体系的药物应用和组分监测方法
KR102107646B1 (ko) 2012-06-15 2020-05-08 이뮤노믹 쎄라퓨틱스, 인크. 알레르기 치료용 핵산
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
JP2017511151A (ja) 2014-03-14 2017-04-20 イムノコア リミテッド Ｔｃｒライブラリ
WO2016057986A1 (en) 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
US20180256716A1 (en) 2015-06-01 2018-09-13 Medigene Immunotherapies Gmbh T-cell receptor specific antibodies
EA201792661A1 (ru) 2015-06-01 2018-05-31 Медиджин Иммьюнотерапиз Гмбх Способ получения антител против т-клеточного рецептора
CN107922950B (zh) 2015-06-01 2021-12-31 基因医疗免疫疗法有限责任公司 T细胞受体文库
JP6697562B2 (ja) 2015-12-23 2020-05-20 メディジーン イミュノテラピーズ ゲーエムベーハー 樹状細胞組成物

Also Published As

Publication number Publication date
US10882891B2 (en) 2021-01-05
AU2016374874B2 (en) 2020-12-03
JP6676759B2 (ja) 2020-04-08
US20190002515A1 (en) 2019-01-03
KR20180089446A (ko) 2018-08-08
HUE053674T2 (hu) 2021-07-28
NZ741954A (en) 2020-04-24
WO2017109110A1 (en) 2017-06-29
TW201736595A (zh) 2017-10-16
AU2016374873B2 (en) 2020-12-24
KR20180093954A (ko) 2018-08-22
TWI752930B (zh) 2022-01-21
CA3009542C (en) 2023-08-29
WO2017109109A1 (en) 2017-06-29
CA3009564A1 (en) 2017-06-29
EA201891459A1 (ru) 2018-11-30
EP3394247A1 (en) 2018-10-31
PH12018501336A1 (en) 2019-02-18
EA201891460A1 (ru) 2018-12-28
EP3394248B1 (en) 2021-02-10
CN108473960A (zh) 2018-08-31
EP3901254A1 (en) 2021-10-27
PL3394248T3 (pl) 2021-09-13
KR102319839B1 (ko) 2021-11-01
ES2865484T3 (es) 2021-10-15
MX2018007842A (es) 2018-11-09
JP2020114222A (ja) 2020-07-30
CN108603171A (zh) 2018-09-28
JP6697562B2 (ja) 2020-05-20
PL3394247T3 (pl) 2021-08-23
AU2016374874A1 (en) 2018-05-17
EP3889253A1 (en) 2021-10-06
JP2018538001A (ja) 2018-12-27
JP2018537999A (ja) 2018-12-27
PH12018501335A1 (en) 2019-02-18
EP3394247B1 (en) 2021-02-10
US20190000949A1 (en) 2019-01-03
BR112018012694A2 (pt) 2018-12-04
AU2016374873A1 (en) 2018-05-17
US11155589B2 (en) 2021-10-26
EP3394248A1 (en) 2018-10-31
TW201736594A (zh) 2017-10-16
CA3009564C (en) 2023-08-29
TWI772282B (zh) 2022-08-01
KR20200100858A (ko) 2020-08-26
NZ741955A (en) 2020-04-24
DK3394247T3 (da) 2021-04-12
DK3394248T3 (da) 2021-04-19
KR20200085362A (ko) 2020-07-14
CA3009542A1 (en) 2017-06-29
MX2018007841A (es) 2018-11-09
ES2863733T3 (es) 2021-10-11

Similar Documents

Publication Publication Date Title
BR112018012826A2 (pt) método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1
Burr et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
CY1122790T1 (el) Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις
CO2020001491A2 (es) Molécula de polipéptido con especificidad dual mejorada
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
BR112018008442A2 (pt) receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
BR112015019603A2 (pt) Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna
MX2018001009A (es) Agentes terapeuticos.
CY1122612T1 (el) Μεθοδος
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
PE20151613A1 (es) Construcciones de anticuerpos para cdh19 y cd3
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
BR112017023131A2 (pt) anticorpos anti- fcrn
EA202090757A1 (ru) T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
AR116048A1 (es) Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
CY1120212T1 (el) Πεπτιδια
CL2018001533A1 (es) Nuevos péptidos y combinación de péptidos para el uso en la inmunoterapia contra varios tipos de cáncer
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
MX2019007924A (es) Vacunas contra la influenza.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements